Zoetis ZTS
NYSE ZTS
$75.69 -0.99 (-1.29%)
At close: Aug 20, 2026 · 10:53 AM UTC

Zoetis (ZTS) Non-Current Deferred Tax Liability (2012 - 2026)

Zoetis (ZTS) posted quarterly Non-Current Deferred Tax Liability of $130.0 million for Q1 2026, down 19.25% year-over-year from $161.0 million in Q1 2025, and down 5.11% quarter-over-quarter from $137.0 million in Q4 2025.

Zoetis (ZTS) Non-Current Deferred Tax Liability (2012 - 2026) Analysis & Trends

Zoetis (ZTS) has reported Non-Current Deferred Tax Liability for 15 consecutive years, with $130.0 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Non-Current Deferred Tax Liability fell 19.25% year-over-year to $130.0 million; the TTM figure through Mar 2026 stood at $130.0 million (down 19.25% YoY), while the FY2025 annual figure was $137.0 million, down 17.96% from the prior year.
  • Non-Current Deferred Tax Liability slipped to $130.0 million in Q1 2026 per ZTS's latest filing, from $137.0 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $287.0 million in Q1 2022 and bottomed at $121.0 million in Q2 2023.
  • Historically, Non-Current Deferred Tax Liability has averaged $170.5 million across 5 years, with a median of $156.0 million in 2025.
  • Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability slumped 55.84% — and 2024, when it soared 44.63%.
  • Zoetis' Non-Current Deferred Tax Liability stood at $142.0 million in 2022, then gained by 2.82% to $146.0 million in 2023, then gained by 14.38% to $167.0 million in 2024, then dropped by 17.96% to $137.0 million in 2025, then declined by 5.11% to $130.0 million in 2026.
  • Business Quant data shows ZTS's Non-Current Deferred Tax Liability at $130.0 million in Q1 2026, $137.0 million in Q4 2025, and $147.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 43.76 Bn 42.79 Bn -
2 Teva Pharmaceutical Industries 43.38 Bn 39.73 Bn 2.15 Bn
3 Zoetis 31.61 Bn 29.93 Bn 1.05 Bn
4 Takeda Pharmaceutical 28.64 Bn 22.84 Bn 5.10 Bn
5 United Therapeutics 22.20 Bn 19.54 Bn 683.80 Mn
6 Viatris 18.82 Bn 17.93 Bn 1.46 Bn
7 Neurocrine Biosciences 15.67 Bn 15.28 Bn 935.80 Mn
8 Elanco Animal Health 12.11 Bn 11.58 Bn 798.00 Mn
9 Dr Reddys Laboratories 10.10 Bn 9.94 Bn -
10 Alkermes 8.21 Bn 7.55 Bn 397.90 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 122.00 Mn
Jun 30, 2026 122.00 Mn
Mar 31, 2026 130.00 Mn
Mar 31, 2026 130.00 Mn
Dec 31, 2025 137.00 Mn
Dec 31, 2025 137.00 Mn
Sep 30, 2025 147.00 Mn
Sep 30, 2025 147.00 Mn
Jun 30, 2025 156.00 Mn
Jun 30, 2025 156.00 Mn
Mar 31, 2025 161.00 Mn
Mar 31, 2025 161.00 Mn
Dec 31, 2024 167.00 Mn
Dec 31, 2024 167.00 Mn
Sep 30, 2024 172.00 Mn
Sep 30, 2024 172.00 Mn
Jun 30, 2024 175.00 Mn
Jun 30, 2024 175.00 Mn
Mar 31, 2024 136.00 Mn
Mar 31, 2024 136.00 Mn